TW201828985A - 在抗pd-l1/pd1治療失敗後以抗csf-1r抗體與抗pd-l1抗體之組合進行腫瘤之治療 - Google Patents

Info

Publication number

TW201828985A

TW201828985A TW106144999A TW106144999A TW201828985A TW 201828985 A TW201828985 A TW 201828985A TW 106144999 A TW106144999 A TW 106144999A TW 106144999 A TW106144999 A TW 106144999A TW 201828985 A TW201828985 A TW 201828985A

Authority

TW

Taiwan

Prior art keywords

csf

antibody

seq

cancer

antagonist

Prior art date

2016-12-22

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims description 179
• 238000011282 treatment Methods 0.000 title claims description 154
• 238000002648 combination therapy Methods 0.000 claims abstract description 78
• 239000003814 drug Substances 0.000 claims abstract description 41
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims abstract description 6
• 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims abstract 4
• 102000008096 B7-H1 Antigen Human genes 0.000 claims description 198
• 108010074708 B7-H1 Antigen Proteins 0.000 claims description 198
• 239000005557 antagonist Substances 0.000 claims description 179
• 201000011510 cancer Diseases 0.000 claims description 120
• 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 58
• 210000002540 macrophage Anatomy 0.000 claims description 49
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 37
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 37
• 239000012270 PD-1 inhibitor Substances 0.000 claims description 34
• 239000012668 PD-1-inhibitor Substances 0.000 claims description 34
• 229940121655 pd-1 inhibitor Drugs 0.000 claims description 34
• 239000012271 PD-L1 inhibitor Substances 0.000 claims description 30
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 30
• 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 30
• 206010005003 Bladder cancer Diseases 0.000 claims description 25
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 25
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 25
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 25
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 24
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 24
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 24
• 229960003852 atezolizumab Drugs 0.000 claims description 20
• 201000001441 melanoma Diseases 0.000 claims description 18
• 229960003301 nivolumab Drugs 0.000 claims description 18
• 230000000694 effects Effects 0.000 claims description 17
• 230000004936 stimulating effect Effects 0.000 claims description 15
• 230000008595 infiltration Effects 0.000 claims description 14
• 238000001764 infiltration Methods 0.000 claims description 14
• 230000028993 immune response Effects 0.000 claims description 8
• 230000036737 immune function Effects 0.000 claims description 7
• 230000001747 exhibiting effect Effects 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 230000004614 tumor growth Effects 0.000 claims description 6
• 229960002621 pembrolizumab Drugs 0.000 claims description 3
• 229950009791 durvalumab Drugs 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 25
• 239000003112 inhibitor Substances 0.000 abstract description 8
• 238000006471 dimerization reaction Methods 0.000 abstract description 6
• 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 abstract description 3
• 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 abstract description 3
• 206010066901 Treatment failure Diseases 0.000 abstract description 2
• 210000004027 cell Anatomy 0.000 description 57
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 49
• 238000000034 method Methods 0.000 description 45
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 40
• 238000002560 therapeutic procedure Methods 0.000 description 35
• 230000004044 response Effects 0.000 description 28
• 238000009097 single-agent therapy Methods 0.000 description 28
• 208000037821 progressive disease Diseases 0.000 description 26
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 22
• 102000048776 human CD274 Human genes 0.000 description 21
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 19
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 19
• 210000004981 tumor-associated macrophage Anatomy 0.000 description 18
• -1 PLCy Proteins 0.000 description 16
• 239000012634 fragment Substances 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• 206010061818 Disease progression Diseases 0.000 description 15
• 239000000427 antigen Substances 0.000 description 15
• 230000005750 disease progression Effects 0.000 description 15
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 14
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 14
• 102000036639 antigens Human genes 0.000 description 14
• 108091007433 antigens Proteins 0.000 description 14
• 210000003719 b-lymphocyte Anatomy 0.000 description 14
• 201000010099 disease Diseases 0.000 description 14
• 108090000623 proteins and genes Proteins 0.000 description 14
• 230000011664 signaling Effects 0.000 description 14
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
• 206010025323 Lymphomas Diseases 0.000 description 13
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 13
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 13
• 201000005202 lung cancer Diseases 0.000 description 13
• 208000020816 lung neoplasm Diseases 0.000 description 13
• 229940124597 therapeutic agent Drugs 0.000 description 13
• 235000018102 proteins Nutrition 0.000 description 12
• 102000004169 proteins and genes Human genes 0.000 description 12
• 108020004414 DNA Proteins 0.000 description 11
• 230000004913 activation Effects 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 230000036039 immunity Effects 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 11
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 9
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 9
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 9
• 101710181549 Interleukin-34 Proteins 0.000 description 9
• 102100033499 Interleukin-34 Human genes 0.000 description 9
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 9
• 239000002246 antineoplastic agent Substances 0.000 description 9
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 229960004562 carboplatin Drugs 0.000 description 9
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
• 229960004316 cisplatin Drugs 0.000 description 9
• 210000004443 dendritic cell Anatomy 0.000 description 9
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 9
• 230000002401 inhibitory effect Effects 0.000 description 9
• 206010006187 Breast cancer Diseases 0.000 description 8
• 208000026310 Breast neoplasm Diseases 0.000 description 8
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 8
• 102100025136 Macrosialin Human genes 0.000 description 8
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 8
• 150000001413 amino acids Chemical class 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 229940127089 cytotoxic agent Drugs 0.000 description 8
• 229960005277 gemcitabine Drugs 0.000 description 8
• 102000048362 human PDCD1 Human genes 0.000 description 8
• 210000001616 monocyte Anatomy 0.000 description 8
• 150000007523 nucleic acids Chemical class 0.000 description 8
• 238000011084 recovery Methods 0.000 description 8
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 8
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• 229930012538 Paclitaxel Natural products 0.000 description 7
• 206010035226 Plasma cell myeloma Diseases 0.000 description 7
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
• 238000011260 co-administration Methods 0.000 description 7
• 229960002949 fluorouracil Drugs 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 206010061289 metastatic neoplasm Diseases 0.000 description 7
• 239000000203 mixture Substances 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 229960001592 paclitaxel Drugs 0.000 description 7
• 230000036961 partial effect Effects 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 208000000649 small cell carcinoma Diseases 0.000 description 7
• 230000004083 survival effect Effects 0.000 description 7
• 229960003048 vinblastine Drugs 0.000 description 7
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 6
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 6
• 229940045513 CTLA4 antagonist Drugs 0.000 description 6
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
• 108010074328 Interferon-gamma Proteins 0.000 description 6
• 210000004322 M2 macrophage Anatomy 0.000 description 6
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
• 206010061535 Ovarian neoplasm Diseases 0.000 description 6
• 206010041067 Small cell lung cancer Diseases 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 230000014509 gene expression Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 208000000587 small cell lung carcinoma Diseases 0.000 description 6
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
• 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
• 208000034578 Multiple myelomas Diseases 0.000 description 5
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 229960003668 docetaxel Drugs 0.000 description 5
• 229960004679 doxorubicin Drugs 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 229960005420 etoposide Drugs 0.000 description 5
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 102000053925 human CSF1 Human genes 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 229960004964 temozolomide Drugs 0.000 description 5
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
• 208000011691 Burkitt lymphomas Diseases 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 102100037850 Interferon gamma Human genes 0.000 description 4
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000003042 antagnostic effect Effects 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 238000002591 computed tomography Methods 0.000 description 4
• 230000016396 cytokine production Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 230000003394 haemopoietic effect Effects 0.000 description 4
• 102000046699 human CD14 Human genes 0.000 description 4
• 208000003747 lymphoid leukemia Diseases 0.000 description 4
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 4
• 208000021937 marginal zone lymphoma Diseases 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 230000026731 phosphorylation Effects 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 229960004528 vincristine Drugs 0.000 description 4
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 3
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 101000998132 Homo sapiens Interleukin-34 Proteins 0.000 description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 description 3
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
• 206010038389 Renal cancer Diseases 0.000 description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 229940123237 Taxane Drugs 0.000 description 3
• 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 210000003690 classically activated macrophage Anatomy 0.000 description 3
• 230000024203 complement activation Effects 0.000 description 3
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
• 229960003957 dexamethasone Drugs 0.000 description 3
• 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 108700024553 fms Genes Proteins 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 201000010536 head and neck cancer Diseases 0.000 description 3
• 208000014829 head and neck neoplasm Diseases 0.000 description 3
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
• 239000000710 homodimer Substances 0.000 description 3
• 102000002580 human interleukin-34 Human genes 0.000 description 3
• 229960001101 ifosfamide Drugs 0.000 description 3
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 229940072221 immunoglobulins Drugs 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 229960004768 irinotecan Drugs 0.000 description 3
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
• 201000010982 kidney cancer Diseases 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 210000002997 osteoclast Anatomy 0.000 description 3
• 229960005079 pemetrexed Drugs 0.000 description 3
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 238000004393 prognosis Methods 0.000 description 3
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 201000011549 stomach cancer Diseases 0.000 description 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
• 208000002918 testicular germ cell tumor Diseases 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 229960002066 vinorelbine Drugs 0.000 description 3
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 3
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 206010065687 Bone loss Diseases 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 201000003791 MALT lymphoma Diseases 0.000 description 2
• 108091054438 MHC class II family Proteins 0.000 description 2
• 102000043131 MHC class II family Human genes 0.000 description 2
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
• 206010027406 Mesothelioma Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 208000010191 Osteitis Deformans Diseases 0.000 description 2
• 208000027067 Paget disease of bone Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 206010057249 Phagocytosis Diseases 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
• 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 229940122803 Vinca alkaloid Drugs 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000001919 adrenal effect Effects 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 229960000473 altretamine Drugs 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 208000016738 bone Paget disease Diseases 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 238000002619 cancer immunotherapy Methods 0.000 description 2
• 208000035269 cancer or benign tumor Diseases 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000011284 combination treatment Methods 0.000 description 2
• 230000004154 complement system Effects 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 229960005061 crizotinib Drugs 0.000 description 2
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 201000004101 esophageal cancer Diseases 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 238000009093 first-line therapy Methods 0.000 description 2
• 229960002074 flutamide Drugs 0.000 description 2
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
• 201000003444 follicular lymphoma Diseases 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 244000144980 herd Species 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 229940047122 interleukins Drugs 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 208000003849 large cell carcinoma Diseases 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
• 229960001756 oxaliplatin Drugs 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 229960002340 pentostatin Drugs 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 230000008782 phagocytosis Effects 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 230000000979 retarding effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 238000009094 second-line therapy Methods 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 description 2
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 2
• 229950001353 tretamine Drugs 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 206010046885 vaginal cancer Diseases 0.000 description 2
• 208000013139 vaginal neoplasm Diseases 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
• XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• GXMBXAFPYICUDZ-UHFFFAOYSA-N 2,2-dichloro-n-methylethanamine Chemical compound CNCC(Cl)Cl GXMBXAFPYICUDZ-UHFFFAOYSA-N 0.000 description 1
• CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• 230000007730 Akt signaling Effects 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 102000005738 B7 Antigens Human genes 0.000 description 1
• 108010045634 B7 Antigens Proteins 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 108700031361 Brachyury Proteins 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 208000001382 Experimental Melanoma Diseases 0.000 description 1
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 101150019209 IL13 gene Proteins 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 108030003815 Inositol 3-kinases Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
• UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010059282 Metastases to central nervous system Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
• 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
• 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 208000003076 Osteolysis Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 229940123751 PD-L1 antagonist Drugs 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 208000006735 Periostitis Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
• 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 208000019802 Sexually transmitted disease Diseases 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 201000011683 Small Cell Sarcoma Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 239000004268 Sodium erythorbin Substances 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
• 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
• 102100024547 Tensin-1 Human genes 0.000 description 1
• 108010088950 Tensins Proteins 0.000 description 1
• PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
• 206010046392 Ureteric cancer Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 229960001686 afatinib Drugs 0.000 description 1
• ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229960001611 alectinib Drugs 0.000 description 1
• KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 229940039407 aniline Drugs 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 229950002916 avelumab Drugs 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 229960002707 bendamustine Drugs 0.000 description 1
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 201000009613 breast lymphoma Diseases 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 229960001292 cabozantinib Drugs 0.000 description 1
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 229960001602 ceritinib Drugs 0.000 description 1
• VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
• 238000010382 chemical cross-linking Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229960002271 cobimetinib Drugs 0.000 description 1
• RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 238000009799 cystectomy Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960002465 dabrafenib Drugs 0.000 description 1
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
• 229950002205 dacomitinib Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000008260 defense mechanism Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 239000012649 demethylating agent Substances 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 229940121647 egfr inhibitor Drugs 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 208000023437 ependymal tumor Diseases 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 230000007608 epigenetic mechanism Effects 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
• GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229960004750 estramustine phosphate Drugs 0.000 description 1
• ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 1
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 101150098203 grb2 gene Proteins 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 208000027671 high grade ependymoma Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
• 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
• 230000031261 interleukin-10 production Effects 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
• 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 230000004089 microcirculation Effects 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 229940124303 multikinase inhibitor Drugs 0.000 description 1
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229960000513 necitumumab Drugs 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 229960004378 nintedanib Drugs 0.000 description 1
• XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 229950000846 onartuzumab Drugs 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229960003278 osimertinib Drugs 0.000 description 1
• DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 201000008017 ovarian lymphoma Diseases 0.000 description 1
• 238000011375 palliative radiation therapy Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 210000004738 parenchymal cell Anatomy 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 150000003058 platinum compounds Chemical class 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 229960002633 ramucirumab Drugs 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000011519 second-line treatment Methods 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 208000037959 spinal tumor Diseases 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 229940034785 sutent Drugs 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 229940066453 tecentriq Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229960001712 testosterone propionate Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 229950005976 tivantinib Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 229960004066 trametinib Drugs 0.000 description 1
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000037426 transcriptional repression Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 229960001099 trimetrexate Drugs 0.000 description 1
• NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
• 210000002993 trophoblast Anatomy 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 230000006433 tumor necrosis factor production Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 201000011294 ureter cancer Diseases 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 229960003862 vemurafenib Drugs 0.000 description 1
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
• 229940065658 vidaza Drugs 0.000 description 1
• 229960000922 vinflunine Drugs 0.000 description 1
• NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• ZPUHVPYXSITYDI-HEUWMMRCSA-N xyotax Chemical compound OC(=O)[C@@H](N)CCC(O)=O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 ZPUHVPYXSITYDI-HEUWMMRCSA-N 0.000 description 1